Evidence map›Paper›PMID 33589520›Full record

ArticleJournal for immunotherapy of cancer2021

αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib.

Juemin Fang, Na Ding, Xinling Guo, Yan Sun, Zhiwei Zhang, Bailu Xie, Zhong Li, Hui Wang, Wei Mao, Zhicai Lin and 6 more

Erratum issued Registry-linked trialOpen access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03615313 (A Clinical Study of PD-1 Antibody Expressing mesoCAR-T Cells for Patients With Mesothelin Positive Advanced Solid Tumors), which is not on this map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03615313 phase1 / phase2unknown statusnot on this map

A Clinical Study of PD-1 Antibody Expressing mesoCAR-T Cells for Patients With Mesothelin Positive Advanced Solid Tumors

TypeinterventionalSponsorShanghai Cell Therapy Research InstituteRan2018 to 2020Enrolled50ConditionsAdvanced Solid TumorArmsPD-1 antibody expressing mesoCAR-T cells
3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Juemin Fang *Department of Medical Oncology, Shanghai Tenth People's Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China.
Na Ding *Department of Medical Oncology, Shanghai Tenth People's Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China.
Xinling Guo *Department of Medical Oncology, Shanghai Tenth People's Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China.
Yan SunCell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China.
Zhiwei ZhangCell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China.
Bailu XieCell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China.
Zhong LiCell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China.
Hui WangDepartment of Medical Oncology, Shanghai Tenth People's Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China.
Wei MaoDepartment of Medical Oncology, Shanghai Tenth People's Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China.
Zhicai LinCell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China.
Fei QinDepartment of Medical Oncology, Shanghai Tenth People's Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China.
Min YuanDepartment of Medical Oncology, Shanghai Tenth People's Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China.
Wenqi ChuCell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China.
Huanlong QinDepartment of Medical Oncology, Shanghai Tenth People's Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China.
Qijun QianCell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China xuqingmd@aliyun.com qian@shcell.com.
Qing XuDepartment of Medical Oncology, Shanghai Tenth People's Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China xuqingmd@aliyun.com qian@shcell.com.
Shanghai Cell Therapy Research Institute · CNTongji University · CNShanghai Tenth People's Hospital · CNShanghai University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological malignancies in China. In particular, advanced/refractory ovarian cancer lacks effective targeted therapies due to the immunosuppressive and proangiogenic tumor microenvironment. Mesothelin (MSLN) has been found to be highly expressive in most EOC. Targeting MSLN by antibodies or chimeric antigen receptor-modified T (CAR-T) cells and immune checkpoint blockades as well as apatinib, an anti-angiogenic drug, have been used in patients with refractory ovarian cancer. Apatinib was reported to promote the infiltration of CD8 CASE PRESENTATION: Here we report a case of refractory EOC in a patient who had relapsed after multiline chemotherapy. The patient received autologous T cells that contained sequences encoding single-chain variable fragments specific for MSLN and full-length antibody for PD-1 (αPD-1). The modified T cells were called αPD-1-mesoCAR-T cells. After infusion, the copy number and PD-1 antibody secretion of the CAR-T cells were increased in the blood. By application of multimodality tumor tracking, MRI of the liver showed shrinkage of metastatic nodules from average diameter of 71.3-39.1 mm at month 2. The patient achieved partial response and survived more than 17 months. IL-6 levels in the patient fluctuated from the baseline to 2-4-folds after treatment, but side effects were mild with only grade 1 hypertension and fatigue.

conclusionαPD-1-mesoCAR-T cell therapy combined with apatinib demonstrates a potential therapeutic effect on advanced refractory ovarian cancer. TRIAL REGISTRATION NUMBER: NCT03615313.

Indexed as

Antibodies, MonoclonalCarcinoma, Ovarian EpithelialFemaleHumansImmunotherapy, AdoptiveInterleukin-6Liver NeoplasmsMesothelinMiddle AgedNeoplasm Recurrence, LocalProgrammed Cell Death 1 ReceptorPyridinesReceptors, Chimeric AntigenT-LymphocytesTreatment OutcomeUp-RegulationAntibodies, MonoclonalapatinibIL6 protein, humanInterleukin-6MesothelinPDCD1 protein, humanProgrammed Cell Death 1 ReceptorPyridinesReceptors, Chimeric AntigenApatinibCAR-Tcase reportschimeric antigenimmunotherapyovarian cancerPD-1receptors

Identifiers

PMID33589520
PMCPMC7887368
OpenAlexW3131115501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.